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ABSTRACT
Introduction Cigarette smoking and oxidative stress are 
common risk factors for the multi- morbidities associated 
with chronic obstructive pulmonary disease (COPD). 
Elevated levels of advanced glycation endproducts 
(AGE) increase the risk of cardiovascular disease (CVD) 
comorbidity and mortality. The enzyme fructosamine-3- 
kinase (FN3K) reduces this risk by lowering AGE levels.
Methods The distribution and expression of FN3K protein 
in lung tissues from stable COPD and control subjects, 
as well as an animal model of COPD, was assessed by 
immunohistochemistry. Serum FN3K protein and AGE 
levels were assessed by ELISA in patients with COPD 
exacerbations receiving metformin. Genetic variants 
within the FN3K and FN3K- RP genes were evaluated 
for associations with cardiorespiratory function in the 
Subpopulations and Intermediate Outcome Measures in 
COPD Study cohort.
Results This pilot study demonstrates that FN3K 
expression in the blood and human lung epithelium 
is distributed at either high or low levels irrespective 
of disease status. The percentage of lung epithelial 
cells expressing FN3K was higher in control smokers 
with normal lung function, but this induction was not 
observed in COPD patients nor in a smoking model of 
COPD. The top five nominal FN3K polymorphisms with 
possible association to decreased cardiorespiratory 
function (p<0.008–0.02), all failed to reach the threshold 
(p<0.0028) to be considered highly significant following 
multi- comparison analysis. Metformin enhanced systemic 
levels of FN3K in COPD subjects independent of their high- 
expression or low- expression status.
Discussion The data highlight that low and high FN3K 
expressors exist within our study cohort and metformin 
induces FN3K levels, highlighting a potential mechanism to 
reduce the risk of CVD comorbidity and mortality.
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) extends beyond the lung and is 
associated with other diseases, such as cardio-
vascular and metabolic diseases.1 Apart from 
known common risk factors, such as cigarette 
smoking, many of the underlying molecular 
mechanisms driving these comorbidities 
remain to be investigated. Oxidative stress is 
a major factor in the pathogenesis of COPD2 
and cigarette smoking affects both systemic 
inflammation and oxidative stress.3 Cigarette 
smoke contains damaging molecules in the 
form of highly reactive carbonyls commonly 
referred to as carbonyl stress or advanced 
glycation endproducts (AGEs), that have 
been linked to, and can accelerate, diabetic 
complications, such as cardiovascular disease 
(CVD).4
An increase in oxidative stress as a result of 
mitochondrial dysfunction in skeletal muscle 
may also increase the risk of developing type 
2 diabetes mellitus through increased insulin 
resistance and subsequent hyperglycaemic.5–7 
Moreover, mitochondrial dysfunction, which 
is accompanied with ROS production and 
an altered metabolic profile by raising ribose 
levels, also occurs in the lungs8 and skeletal 
muscle9 of COPD patients.10 Together this 
can lead to the development of ‘carbonyl 
stress’’ both in the lungs and systemically 
with an increase in AGEs and subsequent 
protein modification2 11 similar to that seen 
in diabetics.12
Key messages
 ► Do lower levels of fructosamine-3- kinase (FN3K) 
expression confer increased risk of cardiovascular 
disease (CVD) in chronic obstructive pulmonary dis-
ease (COPD)?
 ► Different levels of FN3K expression occur in subjects 
which is affected by smoking and disease status 
with potential genetic linkage to increased CVD risk.
 ► Screening for FN3K may help to identifying those 
most at risk of future CVD as well as open up new 
therapeutic opportunities to reduce the risk of CVD 
and mortality in COPD.
U
niversity of London. P
rotected by copyright.
 on N
ovem
ber 30, 2020 at S
t G
eorge's
http://bm
jopenrespres.bm
j.com
/
B
M
J O
pen R
esp R
es: first published as 10.1136/bm
jresp-2020-000714 on 18 N
ovem
ber 2020. D
ow
nloaded from
 
2 Alderawi A, et al. BMJ Open Resp Res 2020;7:e000714. doi:10.1136/bmjresp-2020-000714
Open access
The recently identified enzyme, fructosamine-3- 
kinase (FN3K) and it is homologue FN3K- RP, can limit 
the production of AGEs from reducing sugars, such as 
ribose, by making the intermediate products unstable, 
liberating the native unmodified protein.13 Moreover, 
two recent publications implicate FN3K in maintaining 
NRF-2 function14 and in regulating histone carbonyla-
tion by ribose15 with important epigenetic consequences, 
both of which can impact on cell function. Both isoforms 
of FN3K (FN3K and FN3K- RP) are constitutive expressed 
throughout the human body with the heart and vascu-
lature showing the highest levels of expression (Human 
Protein Atlas and GTEx Portal). Furthermore, variation 
within the FN3K- RP gene has been associated with CVD 
risk traits.16
We previously reported that high FN3K expression in 
diabetic patients was associated with a lower incidence 
of CVD risk factors suggesting that FN3K may be protec-
tive.17 Moreover, a recent study by Sartore et al18 have 
shown similar findings. During acute exacerbations of 
COPD (AECOPD), blood sugar levels and insulin resis-
tance worsens because of the increased physiological 
stresses during acute illness and increased use of corti-
costeroid therapy.19 Such patients are treated with drugs, 
such as metformin, that increase insulin sensitivity and 
help lower blood sugar and corresponding AGE levels.20 
Consequently, metformin has been shown to reduce the 
risk of cardiovascular disease21 as a result of lowering 
AGE levels.22 23
Due to the apparent role of FN3K in reducing the 
levels of AGEs and the potential risk of developing 
CVD we hypothesised that FN3K may play an important 
molecular link for the comorbidity associations between 
CVD and COPD. In order to test this hypothesis, we 
performed a pilot analysis of FN3K protein expression 
in two separate clinical studies, comprised stable COPD 
(study 1) and AECOPD (study 2), as well as in a chronic 
smoking model of COPD. In study 1 we looked at the 
expression of FN3K in non- smokers, smokers and stable 
COPD. Whereas, in study 2 we assessed the impact of 
metformin on FN3K expression in AECOPD, a condi-
tion where blood sugar levels and insulin resistance are 
known to rise. This was then complemented by a study to 
determine if variants in the FN3K and FN3K- RP genes are 
associated with a measure of cardiovascular function in 
COPD patients.
MATERIALS AND METHODS
Human study subjects
Study 1: all subjects provided informed consent and were 
recruited from the Section of Respiratory Medicine of 
the University Hospital of Ferrara, Italy undergoing lung 
resection for a solitary peripheral neoplasm. Thirty- six 
subjects in total consisted of 12 non- smokers with normal 
lung function, 12 smokers with normal lung function and 
12 smokers with moderate (GOLD2) stable COPD. All 
subjects were free from preoperative chemotherapy and/
or radiotherapy and had not been treated with broncho-
dilators, theophylline, antibiotics, antioxidants and/or 
glucocorticoids in the last month before surgery. The 
resected lung tissue samples were fixed in paraffin and 
then blinded in a randomised manner before examina-
tion by immunohistochemistry. This study was part of a 
larger project examining the molecular pathophysiolog-
ical mechanisms of COPD.
Study 2: following informed consent, 23 patients with 
AECOPD and diabetes admitted to St George’s Hospital 
(London) were treated with either metformin or placebo 
in a randomised double- blind manner (16 treated with 
metformin and 7 treated with placebo). Serum samples 
collected on entry (baseline), at discharge (7 days after 
entry) and during follow- up (28 days after discharge) 
were then tested for FN3K protein expression by ELISA. 
This study formed part of a larger study investigating 
the impact of metformin treatment in AECOPD patients 
(clinical trial # NCT01247870) and full details regarding 
patient recruitment, exclusion criteria and dosing regi-
mens are published elsewhere.24
All pulmonary function tests were performed as previ-
ously described.25 Both clinical studies conformed to the 
Declaration of Helsinki with the work being approved by 
the respective institutional ethics committees.
As part of the patient and public involvement policy, 
patients generously provided tissue samples for this study 
following informed consent as detailed previously. The 
patients and public were not involved in the study design, 
conduct, dissemination of results and evaluation of the 
studies.
Animal studies
Eight- week- old C57BL/6J wild type mice were exposed 
to either cigarette smoke or filtered air for 6 months as 
described previously.26 All exposures were approved 
by the local ethical committee at Rochester University, 
USA for work on animals and abided by the Declaration 
of Helsinki. Following the exposure, the animals were 
culled and FN3K expression was determined in periph-
eral lung tissue by immunohistochemistry on slices of 
paraffin fixed lung tissue.
Immunohistochemistry
Immunostaining of formalin fixed paraffin- embedded 
peripheral lung tissue was performed as previously 
described.27 Both human and murine FN3K were detected 
with a rabbit polyclonal anti- FN3K Antibody (catalogue 
no. AP7083a) purchased from Abgent (Cambridge, UK) 
at a dilution of 1.667 µg/mL and 2.5 µg/mL, respec-
tively. Positively stained cells were counted in at least five 
different fields of view and expressed as a percentage of 
total cells for each subject or mouse.
ELISA (for FN3K and carbonyl levels)
FN3K levels in serum was assessed by ELISA using a 
commercial FN3K sandwich- based ELISA kit (catalogue 
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no. CSB- EL008760HU) manufactured by Cusabio Corp 
and purchased from Stratech Scientific (Newmarket, 
UK). Serum samples were diluted 1:5 in assay diluent and 
processed as per manufacturer’s instructions.
Carbonyl (advanced glycated endproducts) levels were 
assessed in serum as per manufacturer’s instructions 
using the OxiSelect protein carbonyl ELISA kit (cata-
logue no. STA-310) purchased from Cambridge Biosci-
ence (Cambridge, UK).
FN3K/FN3KRP genetic association study
Regression- based association testing was undertaken to 
identify associations of 252 FN3K and FN3KRP single 
nucleotide polymorphisms (SNPs) with cardiovascular 
and respiratory exercise performance as measured by the 
six- minute walk test distance (6MWD) as a percentage 
of predicted.28 The study population included an inde-
pendent cohort of 1827 non- Hispanic Whites (NHW) 
and 428 African Americans (AA) defined as at- risk 
smokers with and without COPD from the NHLBI 
(National Heart,Lung and Blood Institute) Subpopu-
lations and Intermediate Outcome Measures in COPD 
Study (SPIROMICS). These subjects had whole- genome 
genotyping data complemented by imputation resulting 
in the genotyping of 252 SNPs within the 34 kB genomic 
region encompassing FN3K and FN3K- RP genes on chro-
mosome 17. This culminated in the representation of 18 
independent, tagging SNPs in NHW and 54 SNPs in AA 
(r2<0.5) within FN3K and FN3KRP.
Statistical analysis on FN3K protein expression data
The statistical analysis was performed using Graph- pad 
Prism V.7 software. Serum FN3K expression data and 
carbonyl level data for AECOPD subjects treated with or 
without metformin were tested for normality at all data 
points using the Shapiro- Wilk normality test. Differences 
between groups (placebo vs metformin) were analysed 
using Tukey’s two- way analysis of variance (ANOVA) 
followed by unpaired t- test (Holm- Sidak method) for 
comparison between groups at each sampling point. 
To determine significant differences within each group 
(either placebo or metformin) with multiple compar-
isons between each time point, one- way ANOVA with 
Tukey’s post hoc analysis was undertaken. For immuno-
histochemical data, the Kruskal- Wallis test was applied 
to determine significant differences in FN3K expression 
between non- smokers, smokers and stable COPD. Mann- 
Whitney U test was applied for comparison of FN3K 
expression between air and cigarette smoke exposed 
mice. Probability values of p<0.05 were considered signif-
icant. To determine qualified comparisons on categor-
ical data for the numbers of subjects allocated as high 
frequency FN3K expressers between the three groups 
(non- smokers, smokers and COPD) a χ2 analysis was 
performed.
RESULTS
FN3K expression is reduced in COPD lung
Immunohistochemical analysis of FN3K expression in 
human peripheral lung tissue indicated that FN3K was 
expressed in airway epithelial cells (figure 1). The level of 
expression of FN3K across all three groups (non- smokers, 
smokers and stable COPD) could be separated into two 
distinct clusters within each group. This was determined 
using a mathematical model of K means cluster anal-
ysis. Across all three groups (non- smokers, smokers and 
Figure 1 Representative immunohistochemical staining 
for fructosamine-3- kinase (FN3K) in bronchiolar epithelial 
cells of stable chronic obstructive pulmonary disease 
(COPD) patients and control subjects (A: non- smoking 
control; B: control smoker with normal lung function; 
C: patients with stable COPD; 100× magnification; bar: 
20 µm). (D) The percentage of FN3K immunopositive 
epithelial cells from peripheral lung sections following 
immunohistochemical staining. Each data point is the 
average score of immunopositive epithelial cells counted 
over several random fields of view for each subject. The 
mean±SEM is overlaid on top of the scatter plot for each 
cohort sub grouping. Each cohort (non- smoker, smoker 
with normal lung function (smoker) and COPD) is split into 
two subgroups, those exhibiting a low frequency of FN3K 
expression (low) and those exhibiting a high frequency of 
FN3K expression (high). Non- parametric Kruskal- Wallis test 
was employed, where applicable, to determine significant 
differences within each cohort subgrouping (**p<0.01). 
(E) The percentage of subjects exhibiting immunopositive 
FN3K expression in >15% of lung epithelial cells, as 
illustrated in(D), between non- smokers (NS), smokers 
with normal lung function (smokers) and stable COPD 
patients (COPD). The numbers in brackets represent the 
mean percentage of FN3K immunopositive epithelial cells 
in each cohort exhibiting high FN3K expression. A χ2 test 
was used to check for independence. The probability of 
independence (p) between the three groups is illustrated.
U
niversity of London. P
rotected by copyright.
 on N
ovem
ber 30, 2020 at S
t G
eorge's
http://bm
jopenrespres.bm
j.com
/
B
M
J O
pen R
esp R
es: first published as 10.1136/bm
jresp-2020-000714 on 18 N
ovem
ber 2020. D
ow
nloaded from
 
4 Alderawi A, et al. BMJ Open Resp Res 2020;7:e000714. doi:10.1136/bmjresp-2020-000714
Open access
COPD) the two clusters that were identified could be 
defined into those that had a low frequency (<15%) of 
FN3K positive airway epithelial cells and those that had 
a high frequency (≥15%) of FN3K positive airway epithe-
lial cells (figure 1D). Further analysis revealed that the 
15% cut- off was at least two SD away from the means of 
all samples allocated to clusters with a low frequency of 
FN3K positive cells within each group. In keeping with 
this definition, in healthy non- smokers, 83% (10 of 12) of 
subjects expressed very little FN3K with only 2.2%±1.4% 
of airway epithelial cells expressing FN3K. Whereas, 17% 
(2 of 12) of non- smokers expressed FN3K with 66%±7% 
of epithelial cells staining positive for FN3K. In contrast, 
75% (9 of 12) of smokers were positive for FN3K expres-
sion exhibiting a significant (p<0.05) increase in FN3K 
expression with 31.3%±6.3% of epithelial staining posi-
tive for FN3K compared with 2.0%±1% of epithelial cells 
expressing FN3K in the 25% of smokers defined as low 
FN3K expressers. In the stable COPD group, the number 
of subjects still exhibiting widespread expression of FN3K 
fell to 33% (4 of 12) with 50%±11% of epithelial cells 
expressing FN3K. Consequently, 67% (8 of 12) of the 
COPD subjects had significantly lower (p<0.05) levels of 
FN3K expression with only 4.1%±2% of epithelial cells 
expressing FN3K.
Figure 1E illustrates the impact of these results by 
expressing the percentage of subjects in each group 
expressing high levels of epithelial FN3K expression. A 
χ2 analysis was performed to examine the relationship 
in the number of subjects identified as high frequency 
FN3K expressers between all three groups (non- smokers, 
smokers and COPD). This demonstrated that that 
there was a significant association between smoking 
and high levels of FN3K expression when compared 
with non- smokers (χ2 (1, N=24)=8.22; p=0.004) and COPD 
(χ2 (1, N=24)=4.20; p=0.04). These results would imply that 
smoking induces expression of FN3K in airway epithelial 
cells, presumable as a protective mechanism in order to 
combat the increased levels of carbonyl stress/AGEs that 
are present and formed by cigarette smoke.4 However, 
the ability to maintain FN3K expression and therefore a 
protective mechanism to combat the increased levels of 
carbonyl stress or AGEs in lung epithelial cells appears to 
have been lost in a number of subjects with stable COPD. 
Interestingly, in those subjects with stable COPD that 
still maintained an elevated level of FN3K expression, 
there was a more widespread expression of FN3K with 
more epithelial cells (50%) staining positive for FN3K 
compared with smokers with 33% of lung epithelial cells 
expressing FN3K.
Metformin induces increased expression of FN3K in AECOPD
In study 2 involving 23 subjects with AECOPD and 
diabetets, metformin significantly (p<0.0001) enhanced 
systemic FN3K expression over a 35- day period from 
initial trial entry to follow- up following discharge 
(figure 2A). In contrast, those subjects given placebo 
Figure 2 Impact of metformin (A) versus placebo (B) 
on serum fructosamine-3- kinase (FN3K) levels in chronic 
obstructive pulmonary disease (COPD) patients with an 
acute exacerbation. Data are plotted as the mean±SEM 
for FN3K protein expression as assessed by ELISA at 
each of the sampling points. Entry was at day 1, with a 
median discharge at day 7 (days 4–10) and follow- up at 
day 35. Data are expressed as ng/mL FN3K (A and B) 
and per cent change from baseline entry (C). In (A) and 
(B) one way analysis of variance (ANOVA) and Tukey’s 
multiple comparison test was used to determine significant 
changes relative to entry within each group (either placebo 
or metformin. A p<0.05 was considered significant 
(†††p<0.001, ††††p<0.0001). (C) Statistical analysis was 
performed using two way ANOVA and Sidak’s multiple 
comparison test across both placebo and metformin 
groups to test for significant differences between placebo 
(∎) and metformin (●) at each sampling point. A p<0.05 was 
considered significant (*p<0.05).
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(figure 2B) showed no significant change in systemic 
FN3K expression over the same time period. Further-
more, this increase in FN3K expression in the metformin 
treated group was significantly (p<0.05) higher than 
the levels observed in the placebo group at both the 
discharge and follow- up sampling points. We have previ-
ously shown that fructosamine levels were significantly 
reduced in the metformin treated group from trial entry 
to follow- up, unlike the placebo group which showed no 
significant reduction.24 Further analysis here revealed 
that systemic levels of carbonyl were also significantly 
(p<0.001) reduced by 61% at follow- up compared with 
trial entry in the metformin treated subjects (figure 3). 
Carbonyl levels also significantly (p<0.01) fell over the 
same time period in the placebo group, but only by 50%. 
The 11% greater fall in carbonyl levels in the metformin 
group compared with the placebo group at the follow- up 
time point just failed to reach significance (p=0.08).
FN3K expression is reduced in the lungs of cigarette smoke 
exposed mice
In order to ascertain whether the reduction in FN3K 
expression in COPD lung was a disease related event, we 
looked to see if it could be replicated in an animal model 
of COPD. Using mice that were chronically exposed to 
cigarette smoke for 6 months and exhibiting many of the 
pathological features of COPD as previously reported,26 
we looked at expression of FN3K in peripheral lung tissue 
by immunohistochemistry. Figure 4 shows that in mice, 
following a 6- month exposure to cigarette smoke there 
was a significant reduction (p<0.05) in FN3K expression 
in airway epithelial cells compared with mice exposed 
to filtered air over the same time period. This suggests 
that over a long period of time, cigarette smoke may be 
causing a reduction in FN3K protein expression, either 
through increased proteolysis or through a negative 
impact on gene expression at the epigenetic or transcrip-
tional levels.
Association of FN3K SNPs in COPD with cardiovascular 
function
Table 1 illustrates the top five independent nominal SNP 
associations with per cent predicted 6MWD (p=0.008 to 
0.02) in the SPIROMICS data set. However, these associa-
tions did not meet the significance threshold for multiple 
comparisons (p=0.0028 in Whites, p=9.3×10−4 in AA). 
Moreover, the top five SNPs were not replicated in inde-
pendent cohorts from COPDGene, GENKOLS, ECLIPSE 
or NETT individually or with meta- analysis (p>0.05). 
Nevertheless, one SNP on FN3K- RP (rs1046875) tagged 
for two additional SNPs (rs1046896 and rs1046917) that 
were all previously associated with increased HbA1c 
and a corresponding increased risk of coronary artery 
disease.29 30
DISCUSSION
In this pilot study, FN3K protein was detected both in 
the lungs and systemically in COPD. The levels of FN3K 
positive (FN3K+) epithelial cells in non- smoker, smoker 
and COPD airways separated into two distinct pheno-
types: very low or high numbers of FN3K+ positive cells. 
However, a similar separation was not seen in the smaller 
number of COPD subjects in the metformin study. This 
separation of FN3K+ subjects into two distinct groups is 
similar to that reported in diabetic subjects.17 Moreover, 
these phenotypes correlated with cardiovascular risk, 
Figure 3 Impact of metformin (A) versus placebo (B) 
on serum protein carbonyl levels in chronic obstructive 
pulmonary disease (COPD) patients with an acute 
exacerbation as measured by ELISA. Data are plotted 
as a scatter plot with mean±SEM (A and B) and per cent 
change from baseline entry (C). Placebo is represented by 
solid squares and metformin treatment by solid circles in 
(C). Entry was at day 1, with a median discharge at day 7 
(days 4–10) and follow- up at day 35. To test for significant 
difference, one way repeated measures analysis of variance 
was performed with Tukey’s post hoc analysis. A p<0.05 
was considered significant (****p<0.0001).
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whereby low FN3K expression was associated with a larger 
G- gap and greater cardiovascular risk and vice versa.17
The accumulation and increased presence of AGEs 
or carbonyl stress along with the corresponding patho-
physiological mechanisms are well documented31 and a 
known risk factor for developing CVD.23 In diabetes the 
formation of AGEs is linked to high glucose levels and 
the presence of oxidative stress through a process known 
as glycation. However, in COPD high levels of carbonyl 
stress are also present as a result of chronic inflamma-
tion, oxidative stress2 and elevated ribose levels resulting 
from metabolic reprogramming.10 Ribose is 20 times 
more reactive than glucose in glycating proteins and 
forming AGE/carbonyl adducts.32 Consequently, both 
COPD and diabetes are influenced by inflammation and 
oxidative stress resulting in increased carbonyl stress 
and AGEs although they are driven through different 
aetiological stimuli (figure 5). Increased carbonyl stress 
and AGEs have been linked to CVD23 as well as many 
other comorbidities associated with COPD.33 As FN3K 
is widely expressed throughout the body, it is plausible 
that FN3K may be functioning as a protective clearance 
mechanism to remove the damaging precursors to AGE 
formation and that low levels of FN3K expression will 
lead to increased CVD risk (figure 5). In support of our 
hypothesis is the observation that in control smokers 
with normal lung function, we observed an increase in 
the numbers of cells expressing FN3K protein within the 
lower airways, presumably to protect from the increase 
in carbonyl stress and AGE levels. However, this protec-
tive mechanism would appear to be impaired in COPD 
Figure 4 Fructosamine-3- kinase (FN3K) expression 
is reduced in murine airway epithelial cells exposed to 
cigarette smoke for 6 months. C57BL/6J wild type mice 
were exposed to cigarette smoke (CS) or ambient air (Air) 
for 6 months the percentage of airway epithelial cells 
staining positive for FN3K expression in peripheral lung 
sections following immunohistochemical staining was 
recorded over several random fields of view for each mouse 
and the data expressed as the mean±SEM (N=8 for each 
group). Further details are in the Materials and methods 
section. Statistical significance was determined using 
Mann- Whitney U test (*p<0.05).
Table 1 Top genetic associations of FN3K and FN3KRP tagging single nucleotide polymorphisms with six- minute walk 
distance (6MWD) in non- Hispanic Whites from Subpopulations and Intermediate Outcome Measures in COPD Study (MAF = 
Mean Allele Frequency)
Non- Hispanic Whites (N=1827) Mean 6MWD % predicted (SD)
rs number Gene Function MAF N=AA/AB/BB A/A A/B B/B P value
rs73361138 FN3KRP intron 0.03 1729/96/2 84.1 (28.1) 91.4 (27.8) 78.7 (11.6) 0.02
rs1046875 FN3KRP 3UTR 0.32 851/791/185 83.2 (26.0) 84.8 (29.9) 88.8 (28.9) 0.02
rs7794 FN3KRP 3UTR 0.38 724/829/274 85.6 (29.1) 84.9 (28.4) 80.1 (23.9) 0.008
rs7208565 FN3K intron 0.32 850/793/184 83.1 (25.9) 85.0 (30.0) 88.5 (29.0) 0.01
rs2263122 FN3K intron 0.47 536/880/411 82.1 (24.3) 85.2 (30.4) 85.9 (27.4) 0.02
COPD, chronic obstructive pulmonary disease; FN3K, fructosamine-3- kinase.
Figure 5 Fructosamine-3- kinase (FN3K) as a potential 
gatekeeper to prevent the accumulation of damaging 
AGEs that may predispose subjects to increased risk 
of cardiovascular disease. Accumulation of AGEs and 
carbonyl stress may come directly through raised 
uncontrolled blood glucose levels in diabetes or indirectly 
through chronic oxidative stress from cigarette smoking 
in COPD resulting in mitochondrial dysfunction, an altered 
metabolic profile and elevated cellular ribose levels and 
increased carbonyl stress. AGE, advanced glycation 
endproduct; COPD, chronic obstructive pulmonary disease; 
CVD, cardiovasculardisease.
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as the numbers of FN3K+ cells in the lung were reduced. 
Furthermore, this downregulation in the numbers of 
FN3K+ cells was modelled in a chronic smoking model of 
COPD. This might suggest that pathophysiological mech-
anisms prevalent in COPD to trigger downregulation 
in FN3K expression are being replicated in the chronic 
cigarette smoke exposure animal model used here. We 
have previously shown that both oxidative stress and 
carbonyl levels are elevated in the chronic smoke expo-
sure model.34 Clearly further investigation is warranted 
into how chronic exposure to oxidative stress/cigarette 
smoke can lead to down regulation in FN3K expression. 
Consequently, as a result of our findings reported here, 
the chronic smoking model may provide a suitable plat-
form for further investigations. Indeed, little is known 
about the mechanisms controlling FN3K expression but 
a complex interaction between SNPs within the FN3K 
locus, inducible protective mechanisms upregulating 
FN3K expression and activity in response to cigarette 
smoke and epigenetic changes may exist.35 It is also likely 
that oxidative stress may have a direct impact on FN3K 
activity. However, a limitation in the findings reported 
here was that there was insufficient sample to measure 
FN3K enzymic activity. To try and address a possible 
linkage between FN3K SNPs and CVD risk in COPD, we 
analysed the genotyping data from the SPIROMICS cohort 
consisting of at- risk smokers and COPD subjects. 6MWD 
is a measure of cardiorespiratory function determined 
by multiple factors that when evaluated in the context 
of the CVD risk factors determined by FN3K /FN3K- RP 
(body mass index, haemoglobin A1C, systolic blood pres-
sure) it precludes these loci as genetic determinants for 
6MWD.16 While 6MWD was the only data available to us at 
the time within this study cohort, a more reliable marker 
of CVD risk could be evaluated using more detailed 
phenotypes of CVD risk factors in COPD cohorts, such as 
MRI- calcium scores, lipid profiles, haemoglobin A1C or 
CT scan- based measures of adiposity in conjunction with 
multi- omic (transcriptomic/epigenomic) approaches. 
Consequently, our negative findings for FN3K and FN3K- 
RP variation in relation to 6MWD does not exclude an 
indirect contribution leading to increased CVD risk and 
comorbidity. Indeed, one of the SNPs identified in our 
study (rs1046875) is linked to variation associated with 
increased CVD risk traits.29 30
Given that increased ribose levels can accrue in COPD 
subjects as a result of an increase in the pentose phos-
phate pathway10 and poorly controlled diabetics also 
exhibit increased ribose levels, both of which can lead to 
increased AGE and corresponding increased CVD risk.6 
It is plausible that FN3K- RP genetic variation results in 
alterations in ribose derived AGE products subsequently 
linked to CVD risk. While the case is not fully proven here 
in COPD subjects, it does offer the possibility that there 
may still be a linkage, although indirectly, between FN3K 
polymorphisms and CVD risk in COPD subjects. Indeed, 
SNPs in FN3K have been strongly associated with changes 
in sRAGE,36 which in turn has been linked to CVD risk.37 
However, a recent study by Sartore et al18 has reported 
that a cluster of FN3K SNPs when expressed together 
were associated with increased risk of microvascular and 
macrovascular complications. It is possible therefore that 
no single direct linkage between FN3K variation and 
CVD may exist but instead requires interactions between 
different FN3K polymorphisms, and possibly RAGE 
expression as well, to confer increased risk to CVD within 
COPD subjects.
Metformin administration to COPD patients with 
AECOPD significantly increased serum FN3K levels over 
the course of an exacerbation following admission into 
hospital irrespective of the basal level. In contrast, serum 
FN3K levels did not change with placebo. This increase 
was mirrored by a corresponding fall in carbonyl (AGE) 
levels from entry into the study to follow- up in both the 
placebo and metformin groups. Although there was 
a 10% difference in carbonyl levels between the two 
groups, this just failed to reach significance (p=0.08). 
This was in contrast to that seen for fructosamine levels 
in the same study where metformin, but not placebo, 
caused a significant fall in serum fructosamine levels.24 
It is possible that metformin could not have a significant 
effect on carbonyl levels in our study, as the exacerba-
tion and subsequent production of carbonyls had already 
begun before metformin was administered. Indeed, in a 
study by Dallak et al38 when metformin was administered 
prior to the induction of a diabetic state subsequent 
increases in carbonyl (AGE) levels were prevented. This 
failure to reach significance may reflect the importance 
of other unknown mechanisms that aid the resolution 
of the exacerbation episode or that this study was not 
sufficiently powered to detect these changes. Indeed, 
a potential major limitation for the two pilot studies 
involving stable COPD and AECOPD reported here 
were the low number of subjects involved. However, 
post- hoc analysis of statistical power revealed that both 
studies achieved 100% power to discriminate significant 
differences (p<0.001) in FN3K expression between the 
different cohorts under investigation. Metformin has 
been shown to decrease CVD risk and resultant mortality 
in both diabetics and non- diabetics.14 39 40 It is unclear 
how metformin’s impact on FN3K expression may affect 
pathophysiological mechanisms and subsequent comor-
bidity risk of CVD in COPD patients, although Dallak et al 
have shown that metformin can reduce levels of AGEs.38 
Several pathophysiological mechanisms such as endo-
thelial dysfunction and increased coagulopathy within 
the vasculature are associated with increased risk of 
CVD in COPD.41 Moreover, AGEs have been implicated 
in vascular stiffness, atherosclerotic plaque formation, 
thrombogenesis, increased coagulopathy, vascular calci-
fication and endothelial dysfunction with consequential 
impacts on the risk of mortality.42 Therefore, the ability of 
FN3K to remove fructosamine and ribosamine residues 
on modified proteins and thereby reduce the carbonyl 
load and AGE formation may have a clinical impact on 
these pathologies and survivability. Metformin can also 
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directly lower AGE levels by reacting with AGE adducts 
containing dicarbonyls,43 in particular methyl glyoxal,44 a 
highly reactive dicarbonyl and a by- product of increased 
glycolysis,45 a pathway that has been shown to be elevated 
in COPD.10 Given that the manipulation of upstream 
metabolic events involving fructosamine will only impact 
on subsequent AGE formation, and the removal of 
existing ‘long- lived’ AGE/ carbonyls may take consider-
ably more time, a longer time course may therefore be 
needed to observe whether changes in FN3K expression 
would result in notable changes in basal AGE/carbonyl 
levels and in turn clinical outcome. The limitations of 
the present assay in measuring all carbonyls may also be 
inappropriate, and more specific assays detecting unique 
AGE/carbonyl adducts known to be associated with 
increased CVD risk may be more appropriate. However, 
a recent study by Ho et al46 indicated that metformin had 
a beneficial impact on survivability in COPD patients 
with diabetes which may be attributed to the metformin- 
induced increase in FN3K expression reported here, 
thereby reducing AGEs and subsequent mortality.
In conclusion, this pilot study shows that the distri-
bution and expression of FN3K protein in COPD and 
age- matched control subjects (both non- smokers and 
smokers with normal lung function) appears to fall 
into one of two groups, those with low levels of FN3K 
protein or those with high levels of FN3K protein expres-
sion. Moreover, smoking appears to trigger a protective 
mechanism whereby FN3K protein levels are increased, 
but this is apparently lost in most but not all COPD 
subjects. Furthermore, metformin elevates FN3K expres-
sion which can reduce carbonyl stress (AGEs) thereby 
potentially reducing the risk of developing CVD. Clearly 
further work needs to be done to demonstrate that a 
clear mechanistic link is present between carbonyl stress, 
FN3K expression and CVD risk in COPD, with or without 
diabetes, and potentially in ageing where systemic AGE 
levels are also known to rise. Finally, this study highlights 
a potential mechanistic explanation for the benefits of 
providing metformin to lower CVD and other disease 
risks associated with increasing AGE levels in COPD.
Author affiliations
1Department of Biomedical Sciences and Physiology, University of 
Wolverhampton, Wolverhampton, UK
2Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle 
Immagini Morfologiche e Funzionali (BIOMORF), Università di Messina, 
Messina, Italy
3Basic Medical Sciences, St Georges, University of London, London, UK
4Clinical Pharmacology, St George's, University of London, London, UK
5Environmental Medicine, University of Rochester Medical Center, Rochester, 
New York, USA
6Airways Diseases Section, Faculty of Medicine, Imperial College London, 
National Heart and Lung Institute, London, UK
7Clinical and Experimental Medicine, Research Centre on Asthma and COPD, 
University of Ferrara, Ferrara, Italy
8Internal Medicine, Wake Forest Health Sciences, Winston- Salem, North 
Carolina, USA
9Department of Internal Medicine, University of Michigan Health System, Ann 
Arbor, Michigan, USA
Acknowledgements The authors would like to thank the SPIROMICS participants 
and participating physicians, investigators and staff for making this research 
possible. More information about the study and how to access SPIROMICS data 
are at www. spiromics. org. We would like to acknowledge the following current 
and former investigators of the SPIROMICS sites and reading centres: Neil E Alexis, 
MD; Wayne H Anderson, PhD; Mehrdad Arjomandi, MD; Igor Barjaktarevic, MD, 
PhD; R Graham Barr, MD, DrPH; Lori A Bateman, MSc; Surya P Bhatt, MD; Eugene 
R Bleecker, MD; Richard C Boucher, MD; Russell P Bowler, MD, PhD; Stephanie A 
Christenson, MD; Alejandro P Comellas, MD; Christopher B Cooper, MD, PhD; David 
J Couper, PhD; Gerard J Criner, MD; Ronald G Crystal, MD; Claire M Doerschuk, 
MD; Mark T Dransfield, MD; Brad Drummond, MD; Christine M Freeman, PhD; Craig 
Galban, PhD; MeiLan K Han, MD, MS; Nadia N Hansel, MD, MPH; Annette T Hastie, 
PhD; Eric A Hoffman, PhD; Yvonne Huang, MD; Robert J Kaner, MD; Richard E 
Kanner, MD; Eric C Kleerup, MD; Jerry A Krishnan, MD, PhD; Lisa M LaVange, PhD; 
Stephen C Lazarus, MD; Fernando J Martinez, MD, MS; Deborah A Meyers, PhD; 
Wendy C Moore, MD; John D Newell Jr., MD; Robert Paine, III, MD; Laura Paulin, 
MD, MHS; Stephen P Peters, MD, PhD; Cheryl Pirozzi, MD; Nirupama Putcha, MD, 
MHS; Elizabeth C Oelsner, MD, MPH; Wanda K O’Neal, PhD; Sanjeev Raman, MBBS, 
MD; Stephen I Rennard, MD; Donald P Tashkin, MD; J Michael Wells, MD; Robert A 
Wise, MD; and Prescott G Woodruff, MD, MPH. The project officers from the Lung 
Division of the National Heart, Lung, and Blood Institute were Lisa Postow, PhD, and 
Lisa Viviano, BSN.
Contributors AA, CR and PC undertook the experimental work. VEO and JLC 
provided the genetic analysis of the SPIROMICS cohort. GC, EHB, AWH and AP 
provided the clinical samples necessary for the studies. IR developed and provided 
the tissue samples from the animal model studies. GC, IA, JLC, SD and PK designed 
the study. All the authors help contribute to the data analysis, interpretation and 
preparation of the manuscript. PK was the lead investigator for this work.
Funding Genetic analysis was supported by grants from the NIH NHLBI K08 
HL118128 and R01 HL142992. SPIROMICS was supported by contracts from the 
NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, 
HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, 
HHSN268200900019C, HHSN268200900020C), and a grant from the NIH/
NHLBI (U01 HL137880, and supplemented by contributions made through the 
Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; 
Bayer; Bellerophon Therapeutics; Boehringer- Ingelheim Pharmaceuticals; 
Chiesi Farmaceutici S.p.A.; Forest Research Institute; GlaxoSmithKline; Grifols 
Therapeutics; Ikaria; Novartis Pharmaceuticals Corporation; Nycomed GmbH; 
ProterixBio; Regeneron Pharmaceuticals; Sanofi; Sunovion; Takeda Pharmaceutical 
Company; and Theravance Biopharma and Mylan. IA was supported by a Wellcome 
Trust grant# 093080/Z/10/Z, EPSRC (EP/T003189/1) and by the UK MRC (MR/
T010371/1 and G1001367/1). PK was supported by a COPDMAP grant from the UK 
MRC (G1001367/1). EB and AH were supported by a grant from the British Lung 
Foundation (COPD10/7).
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in 
the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Ethics approval Local ethics committee of the University Hospital of Ferrara, Italy. 
South East Research Ethics Committee (reference 10/H1102/62).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information. All data relevent to the study 
are deidentified participant data and are included in the article. Further details are 
available from the corresponding author.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Gaetano Caramori http:// orcid. org/ 0000- 0002- 9807- 327X
Christos Rossios http:// orcid. org/ 0000- 0003- 3470- 3233
REFERENCES
 1 Barnes PJ. Chronic obstructive pulmonary disease: effects beyond 
the lungs. PLoS Med 2010;7:e1000220.
 2 Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest 
2013;144:266–73.
U
niversity of London. P
rotected by copyright.
 on N
ovem
ber 30, 2020 at S
t G
eorge's
http://bm
jopenrespres.bm
j.com
/
B
M
J O
pen R
esp R
es: first published as 10.1136/bm
jresp-2020-000714 on 18 N
ovem
ber 2020. D
ow
nloaded from
 
Alderawi A, et al. BMJ Open Resp Res 2020;7:e000714. doi:10.1136/bmjresp-2020-000714 9
Open access
 3 Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects 
of smoking. Chest 2007;131:1557–66.
 4 Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source 
of toxic reactive glycation products. Proc Natl Acad Sci U S A 
1997;94:13915–20.
 5 Nourooz- Zadeh J, Rahimi A, Tajaddini- Sarmadi J, et al. Relationships 
between plasma measures of oxidative stress and metabolic control 
in NIDDM. Diabetologia 1997;40:647–53.
 6 Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 
diabetes. Science 2005;307:384–7.
 7 Hesselink MKC, Schrauwen- Hinderling V, Schrauwen P. Skeletal 
muscle mitochondria as a target to prevent or treat type 2 diabetes 
mellitus. Nat Rev Endocrinol 2016;12:633–45.
 8 Wiegman CH, Michaeloudes C, Haji G, et al. Oxidative stress- 
induced mitochondrial dysfunction drives inflammation and airway 
smooth muscle remodeling in patients with chronic obstructive 
pulmonary disease. J Allergy Clin Immunol 2015;136:769–80.
 9 Puente- Maestu L, Pérez- Parra J, Godoy R, et al. Abnormal 
mitochondrial function in locomotor and respiratory muscles of 
COPD patients. Eur Respir J 2009;33:1045–52.
 10 Michaeloudes C, Kuo CH, Haji G, et al. Metabolic re- patterning in 
chronic obstructive pulmonary disease airway smooth muscle cells. 
Eur Resp J 2017;50:1700202.
 11 Yao H, Rahman I. Current concepts on oxidative/carbonyl stress, 
inflammation and epigenetics in pathogenesis of chronic obstructive 
pulmonary disease. Toxicol Appl Pharmacol 2011;254:72–85.
 12 Singh VP, Bali A, Singh N, et al. Advanced glycation end products 
and diabetic complications. Korean J Physiol Pharmacol 
2014;18:1–14.
 13 Delpierre G, Collard F, Fortpied J, et al. Fructosamine 3- kinase 
is involved in an intracellular deglycation pathway in human 
erythrocytes. Biochem J 2002;365:801–8.
 14 Sanghvi VR, Leibold J, Mina M, et al. The oncogenic action of 
Nrf2 depends on de- glycation by fructosamine-3- kinase. Cell 
2019;178:807–19.
 15 Maksimovic I, Zheng Q, Trujillo MN, et al. An azidoribose probe to 
track ketoamine adducts in histone ribose glycation. J Am Chem 
Soc 2020;142:9999–10007.
 16 Benton MC, Lea RA, Macartney- Coxson D, et al. Mapping eQTLs in 
the Norfolk island genetic isolate identifies candidate genes for CVD 
risk traits. Am J Hum Genet 2013;93:1087–99.
 17 Dunmore SJ, Al- Derawi AS, Nayak AU, et al. Evidence that 
differences in fructosamine-3- kinase activity may be associated with 
the glycation gap in human diabetes. Diabetes 2018;67:131–6.
 18 Sartore G, Ragazzi E, Burlina S, et al. Role of fructosamine-3- kinase 
in protecting against the onset of microvascular and macrovascular 
complications in patients with T2DM. BMJ Open Diabetes Res Care 
2020;8:e001256.
 19 Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is 
associated with poor outcomes in patients admitted to hospital 
with acute exacerbations of chronic obstructive pulmonary disease. 
Thorax 2006;61:284–9.
 20 Giannarelli R, Aragona M, Coppelli A, et al. Reducing insulin 
resistance with metformin: the evidence today. Diabetes Metab 
2003;29:6S28–6S35.
 21 Beisswenger P, Ruggiero- Lopez D. Metformin inhibition of glycation 
processes. Diabetes Metab 2003;29:6S95–6.
 22 Tanaka Y, Uchino H, Shimizu T, et al. Effect of metformin on 
advanced glycation endproduct formation and peripheral nerve 
function in streptozotocin- induced diabetic rats. Eur J Pharmacol 
1999;376:17–22.
 23 Stirban A, Gawlowski T, Roden M. Vascular effects of advanced 
glycation endproducts: clinical effects and molecular mechanisms. 
Mol Metab 2014;3:94–108.
 24 Hitchings AW, Lai D, Jones PW, et al. Metformin in severe 
exacerbations of chronic obstructive pulmonary disease: a 
randomised controlled trial. Thorax 2016;71:587–93.
 25 Varani K, Caramori G, Vincenzi F, et al. Alteration of adenosine 
receptors in patients with chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med 2006;173:398–406.
 26 Yao H, Chung S, Hwang J- woong, et al. Sirt1 protects against 
emphysema via FOXO3- mediated reduction of premature 
senescence in mice. J Clin Invest 2012;122:2032–45.
 27 Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of 
PI3Kdelta restores glucocorticoid function in smoking- induced 
airway inflammation in mice. Am J Respir Crit Care Med 
2009;179:542–8.
 28 Enright PL, Sherrill DL. Reference equations for the six- minute walk 
in healthy adults. Am J Respir Crit Care Med 1998;158:1384–7.
 29 Ghanbari M, Franco OH, de Looper HWJ, et al. Genetic variations 
in MicroRNA- Binding sites affect microRNA- mediated regulation of 
several genes associated with Cardio- metabolic phenotypes. Circ 
Cardiovasc Genet 2015;8:473–86.
 30 Au Yeung SL, Luo S, Schooling CM. The Impact of Glycated 
Hemoglobin (HbA
1c) on Cardiovascular Disease Risk: A Mendelian 
Randomization Study Using UK Biobank. Diabetes Care 
2018;41:1991–7.
 31 Hegab Z, Gibbons S, Neyses L, et al. Role of advanced glycation 
end products in cardiovascular disease. World J Cardiol 
2012;4:90–102.
 32 Sadowska- Bartosz I, Galiniak S, Bartosz G. Kinetics of glycoxidation 
of bovine serum albumin by glucose, fructose and ribose and its 
prevention by food components. Molecules 2014;19:18828–49.
 33 Dalle- Donne I, Giustarini D, Colombo R, et al. Protein carbonylation 
in human diseases. Trends Mol Med 2003;9:169–76.
 34 Yao H, Arunachalam G, Hwang J- W, et al. Extracellular superoxide 
dismutase protects against pulmonary emphysema by attenuating 
oxidative fragmentation of ECM. Proc Natl Acad Sci U S A 
2010;107:15571–6.
 35 Schamberger AC, Mise N, Meiners S, et al. Epigenetic mechanisms 
in COPD: implications for pathogenesis and drug discovery. Expert 
Opin Drug Discov 2014;9:609–28.
 36 Škrha J, Muravská A, Flekač M, et al. Fructosamine 3- kinase and 
glyoxalase I polymorphisms and their association with soluble RAGE 
and adhesion molecules in diabetes. Physiol Res 2014;63:S283–91.
 37 Fukami K, Yamagishi S- I, Okuda S. Role of AGEs- RAGE system in 
cardiovascular disease. Curr Pharm Des 2014;20:2395–402.
 38 Dallak M, Haidara MA, Bin- Jaliah I, et al. Metformin suppresses 
aortic ultrastrucural damage and hypertension induced by diabetes: 
a potential role of advanced glycation end products. Ultrastruct 
Pathol 2019;43:190–8.
 39 Rena G, Lang CC. Repurposing metformin for cardiovascular 
disease. Circulation 2018;137:422–4.
 40 Han Y, Xie H, Liu Y, et al. Effect of metformin on all- cause and 
cardiovascular mortality in patients with coronary artery diseases: 
a systematic review and an updated meta- analysis. Cardiovasc 
Diabetol 2019;18:96.
 41 Cavaillès A, Brinchault- Rabin G, Dixmier A, et al. Comorbidities of 
COPD. Eur Respir Rev 2013;22:454–75.
 42 Yamagishi S- I, Nakamura N, Suematsu M, et al. Advanced glycation 
end products: a molecular target for vascular complications in 
diabetes. Mol Med 2015;21 Suppl 1:S32–40.
 43 Ruggiero- Lopez D, Lecomte M, Moinet G, et al. Reaction of 
metformin with dicarbonyl compounds. Possible implication in the 
inhibition of advanced glycation end product formation. Biochem 
Pharmacol 1999;58:1765–73.
 44 Beisswenger PJ, Howell SK, Touchette AD, et al. Metformin 
reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 
1999;48:198–202.
 45 Allaman I, Bélanger M, Magistretti PJ. Methylglyoxal, the dark side of 
glycolysis. Front Neurosci 2015;9:23.
 46 Ho T- W, Huang C- T, Tsai Y- J, et al. Metformin use mitigates the 
adverse prognostic effect of diabetes mellitus in chronic obstructive 
pulmonary disease. Respir Res 2019;20:69.
U
niversity of London. P
rotected by copyright.
 on N
ovem
ber 30, 2020 at S
t G
eorge's
http://bm
jopenrespres.bm
j.com
/
B
M
J O
pen R
esp R
es: first published as 10.1136/bm
jresp-2020-000714 on 18 N
ovem
ber 2020. D
ow
nloaded from
 
